MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 535013 | Name: Fempa

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fempa is a bioactive chemical.

Chemical Structure

Fempa
Fempa
CAS#1207345-43-4

Theoretical Analysis

MedKoo Cat#: 535013

Name: Fempa

CAS#: 1207345-43-4

Chemical Formula: C24H25FN2O5

Exact Mass: 440.1748

Molecular Weight: 440.47

Elemental Analysis: C, 65.44; H, 5.72; F, 4.31; N, 6.36; O, 18.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Fempa
IUPAC/Chemical Name
Acetamide, N-((2-(2-fluoroethoxy)-5-methoxyphenyl)methyl)-N-(2-(4-methoxyphenoxy)-3-pyridinyl)-
InChi Key
WDCDJYGFOQXTQD-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H25FN2O5/c1-17(28)27(16-18-15-21(30-3)10-11-23(18)31-14-12-25)22-5-4-13-26-24(22)32-20-8-6-19(29-2)7-9-20/h4-11,13,15H,12,14,16H2,1-3H3
SMILES Code
CC(N(CC1=CC(OC)=CC=C1OCCF)C2=CC=CN=C2OC3=CC=C(OC)C=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 440.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Cardiol. 2017 Jul 1;120(1S):S48-S52. doi: 10.1016/j.amjcard.2017.05.010. Epub 2017 May 17. PMID: 28606344. 2: Rastogi A, Bhansali A. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. Diabetes Ther. 2017 Dec;8(6):1245-1251. doi: 10.1007/s13300-017-0320-1. Epub 2017 Oct 26. PMID: 29076040; PMCID: PMC5688986. 3: Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016 Jul;59(7):1333-1339. doi: 10.1007/s00125-016-3956-x. Epub 2016 Apr 25. Erratum in: Diabetologia. 2016 Jul;59(7):1573-4. PMID: 27112340; PMCID: PMC4901113. 4: Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017 Apr;43(2):99-109. doi: 10.1016/j.diabet.2016.12.010. Epub 2017 Jan 30. PMID: 28153377. 5: Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol. 2016 Jun 4;15:85. doi: 10.1186/s12933-016-0403-8. PMID: 27260022; PMCID: PMC4893211. 6: Scheen AJ. Focus sur l’empagliflozine. Synthèse des analyses post hoc de l’étude cardiovasculaire empa-reg outcome [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME]. Rev Med Liege. 2019 Apr;74(4):185-191. French. PMID: 30997967. 7: Alzaid A. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. Diabetes Technol Ther. 2017 Jun;19(6):324-327. doi: 10.1089/dia.2017.0033. Epub 2017 Mar 16. PMID: 28300428; PMCID: PMC5510032. 8: Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005. PMID: 28526185. 9: Suissa S. Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. Diabetes Care. 2018 Feb;41(2):219-223. doi: 10.2337/dc17-1059. PMID: 29358464. 10: Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. J Med Econ. 2019 Mar;22(3):280-287. doi: 10.1080/13696998.2018.1562817. Epub 2019 Jan 11. PMID: 30575426. 11: Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019 Jan;21(1):136-145. doi: 10.1111/dom.13496. Epub 2018 Sep 6. PMID: 30091172; PMCID: PMC6585831. 12: Kraus CK, Carlisle TE, Carney DM. Emergency Medicine Physician Assistant (EMPA) Postgraduate Training Programs: Program Characteristics and Training Curricula. West J Emerg Med. 2018 Sep;19(5):803-807. doi: 10.5811/westjem.2018.6.37892. Epub 2018 Jul 26. PMID: 30202490; PMCID: PMC6123089. 13: Naing S, Poliyedath A, Khandelwal S, Sigala T. Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians. Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25. PMID: 27701934. 14: Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA- REG OUTCOME. Diabetes Res Clin Pract. 2016 Nov;121:204-214. doi: 10.1016/j.diabres.2016.09.016. Epub 2016 Sep 28. PMID: 27744129. 15: Zhang YJ, Han SL, Sun XF, Wang SX, Wang HY, Liu X, Chen L, Xia L. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Oct;97(43):e12843. doi: 10.1097/MD.0000000000012843. PMID: 30412076; PMCID: PMC6221554. 16: Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. Front Physiol. 2018 Nov 21;9:1575. doi: 10.3389/fphys.2018.01575. PMID: 30519189; PMCID: PMC6259641. 17: Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA- REG OUTCOME trial: Comparison with classic diuretics. Diabetes Metab. 2016 Sep;42(4):224-33. doi: 10.1016/j.diabet.2016.05.006. Epub 2016 Jun 10. PMID: 27291329. 18: Schernthaner G, Schernthaner GH. Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. Herz. 2016 May;41(3):208-16. doi: 10.1007/s00059-016-4427-3. PMID: 27071968; PMCID: PMC4839058. 19: Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018 Mar;61(3):722-726. doi: 10.1007/s00125-017-4509-7. Epub 2017 Dec 2. PMID: 29197997; PMCID: PMC6448958. 20: Oral EA. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Drugs Context. 2016 Sep 2;5:212299. doi: 10.7573/dic.212299. PMID: 27648101; PMCID: PMC5017828.